Literature DB >> 5364727

Relationships between headache and amine changes after administration of reserpine to migrainous patients.

G Curzon, M Barrie, M I Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5364727      PMCID： PMC496589          DOI： 10.1136/jnnp.32.6.555

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  10 in total

1.  ESTIMATION OF 5-HYDROXYTRYPTAMINE IN HUMAN BLOOD.

Authors:  G W ASHCROFT; T B CRAWFORD; J K BINNS; E J MACDOUGALL
Journal:  Clin Chim Acta       Date:  1964-04       Impact factor: 3.786

2.  PROPHYLACTIC TREATMENT OF MIGRAINE BY MEANS OF LYSERGIC ACID DERIVATIVES.

Authors:  F SICUTERI
Journal:  Triangle       Date:  1963-10

3.  Effect of reserpine in therapeutic dosage on excretion of 5-hydroxyindoleacetic acid.

Authors:  A TODRICK; M DICK; A C TAIT
Journal:  Br Med J       Date:  1958-03-01

4.  Human pharmacology of reserpine.

Authors:  T WINSOR
Journal:  Ann N Y Acad Sci       Date:  1954-04-30       Impact factor: 5.691

5.  [Urinary excretion of 5-hydroxyindoleacetic acid during headache attacks induced with trinitroglycerin].

Authors:  S Campus; F Fabris; A Rappelli; L Gastaldi; V Gai; G Nattero
Journal:  Boll Soc Ital Biol Sper       Date:  1967-12-31

6.  Plasma serotonin in migraine and stress.

Authors:  M Anthony; H Hinterberger; J W Lance
Journal:  Arch Neurol       Date:  1967-05

7.  Platelet 5-hydroxytryptamine and adenine nucleotides, serum arginylesterase and plasma 11-hydroxycorticosteroids in migraine.

Authors:  H Hinterberger; M Anthony; M K Vagholkar
Journal:  Clin Sci       Date:  1968-04       Impact factor: 6.124

8.  Sensitivities of the brains of infant and adult rats to the catecholamine-depleting actions of reserpine and tetrabenazine.

Authors:  A S Kulkarni; F E Shideman
Journal:  J Pharmacol Exp Ther       Date:  1966-09       Impact factor: 4.030

9.  Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.

Authors:  D A Curran; H Hinterberger; J W Lance
Journal:  Brain       Date:  1965-12       Impact factor: 13.501

10.  Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine.

Authors:  G Curzon; P Theaker; B Phillips
Journal:  J Neurol Neurosurg Psychiatry       Date:  1966-02       Impact factor: 10.154
  10 in total
  7 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 2.  A basis for migraine therapy- the autonomic theory reappraised.

Authors:  E S Johnson
Journal:  Postgrad Med J       Date:  1978-04       Impact factor: 2.401

3.  Headache.

Authors:  R Atkinson; O Appenzeller
Journal:  Postgrad Med J       Date:  1984-12       Impact factor: 2.401

Review 4.  What is migraine? Controversy and stalemate in migraine pathophysiology.

Authors:  J Edmeads
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

5.  Depressive symptoms and migraine comorbidity among pregnant Peruvian women.

Authors:  Swee May Cripe; Sixto Sanchez; Nelly Lam; Elena Sanchez; Nely Ojeda; Silvia Tacuri; Carmen Segura; Michelle A Williams
Journal:  J Affect Disord       Date:  2009-08-20       Impact factor: 4.839

Review 6.  Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches.

Authors:  T M Speight; G S Avery
Journal:  Drugs       Date:  1972       Impact factor: 9.546

7.  An assessment of platelet aggregation induced by 5-hydroxytryptamine.

Authors:  B P Hilton; J N Cumings
Journal:  J Clin Pathol       Date:  1971-04       Impact factor: 3.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.